BIOVIE INC.

Biovie Inc.

Biotechnology Healthcare Carson City, NV, United States BIVIW (NCM)

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Other Biotechnology Companies

View All →

Frequently Asked Questions

Has BIOVIE INC. had layoffs?
No layoff events have been recorded for BIOVIE INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does BIOVIE INC. have?
BIOVIE INC. has approximately 13 employees.
What industry is BIOVIE INC. in?
BIOVIE INC. operates in the Biotechnology industry, within the Healthcare sector.
Is BIOVIE INC. a publicly traded company?
Yes, BIOVIE INC. is publicly traded under the ticker symbol BIVIW on the NCM.
Where is BIOVIE INC. headquartered?
BIOVIE INC. is headquartered in Carson City, NV, United States at 680 W. Nye Lane, Carson City, NV 89703, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.